2016 American Transplant Congress » Poster Session C: Clinical Science - Kidney Immunosuppression: Induction Therapy

6:00pm-7:00pm

A Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin (rATG) 3mg/Kg vs. 6mg/Kg in Kidney Transplant Patients Under Minimization Maintenance Immunosuppressive Regimen.

T. Sandes-Freitas, J. Junqueira Junior, M. Oliveira, C. Girão, R. Esmeraldo.

6:00pm-7:00pm

A Prospective Randomized, Comparative Trial of High-Dose Mizoribine versus Mycophenolate Mofetil in Combination with Tacrolimus and Basiliximab for Living Donor Renal Transplantation: A Multi-Center Trial.

H. Ishida,¹ K. Tanabe,¹ S. Takahara,² N. Amada,³ K. Takahashi,⁴ H. Toma.⁵

6:00pm-7:00pm

After Alemtuzumab Induction, Tac+MMF Is Superior to CsA+MMF in Pediatric Kidney Transplantation.

M. Kaabak,¹ N. Babenko,¹ A. Zokoyev,¹ R. Shapiro.²

6:00pm-7:00pm

Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.

V. Siddagangaiah,¹ H. Sharma,² N. Lal,¹ J. Rai,¹ M. Howse,¹ D. Ridgway,¹ A. Sharma,¹ A. Hammad,¹ S. Mehra.¹

6:00pm-7:00pm

Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.

I. Yakubu,¹ B. Masters,¹ B. Ravichandran,¹ T. Sparkes,¹ M. Moss,¹ F. Rasetto,¹ S. Jonchhe,¹ B. Thomas,² N. Costa,² D. Leeser,² S. Bartlett,² A. Haririan.²

6:00pm-7:00pm

Anti-Thymocyte Globulin Induction Does Not Increase the Risk of Thrombotic Events in Kidney Transplantation: A Matched Case-Control Study.

J. Iuppa,¹ M. Dokus,² E. Venniro,³ A. Patel,² A. Danzig,⁴ J. Hahn,¹ R. Kashyap,² M. Orloff,² J. Taylor.³

6:00pm-7:00pm

Antithymocyte (ATG) Dose Density in Renal Transplant Recipients (RTR) with Early Graft Dysfunction (EGD).

S. Kuten, S. Patel, R. Knight, D. Nguyen, E. Graviss, H. Podder, A. Gaber.

6:00pm-7:00pm

Clinical Factors That Determine the More Appropriate Induction Agent: ATG versus IL-2 Receptor Antagonists.

S. Bae, A. Massie, S. DiBrito, X. Luo, L. Kucirka, F. Al Ammary, D. Segev.

6:00pm-7:00pm

Comparison of De Novo Donor Specific Antibody Formation for Kidney Transplant Recipients Induced with Thymoglobulin or Basiliximab.

A. Gong, K. Lee, S. Patel, M. Brande, R. Dhawan, C. Parke, M. Smogorzewski, L. Aguirre, B. Duong, S. Alexopolus, Y. Qazi.

6:00pm-7:00pm

Elevated De Novo Donor Specific Antibody After Alemtuzumab Induction in Renal Transplant Recipients.

K. Fabbri, J. Descourouez, M. Jorgenson, R. Redfield.

6:00pm-7:00pm

Evaluation of Dose Dependent Rabbit Anti-Thymocyte Globulin Induction in Risk-Stratified Kidney Transplant Recipients.

I. Gutman, M. Misel, D. McKay, A. Hemming, J. Kerr, K. Mekeel.

6:00pm-7:00pm

Induction Agent Use and Outcomes in Older KT Recipients: Patient and Center Level Associations.

M. McAdams-DeMarco, Q. Huang, X. Luo, B. Orandi, S. Dorry.

6:00pm-7:00pm

Induction Therapy in Low Risk African American Kidney Transplant Recipients: Donor Factors.

F. Al Ammary,¹ S. Bae,¹ A. Massie,¹ N. Dagher,¹ E. King,¹ A. Wiseman,² D. Segev.¹

6:00pm-7:00pm

Induction with T-cell Depletional Agents Is Safe and Efficacious in the Very Elderly Kidney Transplant Recipients: An Analysis of the OPTN Database.

H. Dave, L. Wolfe, H. Fattah, D. Kumar, A. King, M. Levy, A. Cotterell, A. Sharma, C. Bhati, G. Gupta.

6:00pm-7:00pm

Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer.

N. Koyawala,¹ J. Silber,² P. Rosenbaum,¹ R. Bloom,¹ W. Wang,² A. Hill,² S. Nazarian,¹ D. Sawinski,¹ J. Trofe,¹ M. Lim,¹ J. Schold,³ P. Reese.¹

6:00pm-7:00pm

Outcomes in Elderly Renal Transplant Recipients Using Thymoglobulin or Interleukin-2 Receptor Antagonist Induction.

N. Jasiak,¹ J. Thielke,¹ J. Chen,² N. Hilal,¹ S. Salah,¹ D. Wu,¹ E. Benedetti,² P. West-Thielke.^1,2

6:00pm-7:00pm

Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.

N. Jasiak,¹ C. Stromayer,¹ J. Thielke,¹ J. Chen,² J. Chen,¹ B. Talon,¹ R. Rubin-Tobar,¹ E. Benedetti,² P. West-Thielke.^1,2

6:00pm-7:00pm

Pharmakokinetics of Prolonged-Release Formulation of Tacrolimus: Comparison of AUC0-24 and Concentration at 10 Time Points.

K. Unagami,¹ M. Okumi,² M. Furusawa,² T. Hirai,² T. Shimizu,² K. Omoto,² M. Inui,² H. Ishida,² K. Nitta,¹ K. Tanabe.²

6:00pm-7:00pm

Plasma Cell Frequency in Renal Rejection After Treatment with Alemtuzumab.

L. Mugge, A. Zimmerman, N. Varshney, A. Gohara, M. Rees, J. Ortiz.

6:00pm-7:00pm

Quality Assessment and Process Improvement of Thymoglobulin Dosing.

H. Sarumi, L. Beck, C. Borscheid, B. Fast, S. Hogan, M. James, K. Vassar, D. Vock, T. Pruett.

6:00pm-7:00pm

Reduced CMV Infection Using Single Low-Dose of Rabbit Anti-Thymocyte Globulin in Kidney Transplanted Recipients.

M. Paula, C. Felipe, M. Cristelli, P. Orlandi, L. Viana, G. Basso, P. Carvalho, C. Montenegro, A. Lima, I. Pietrobom, H. Tedesco-Silva, J. Medina-Pestana.

6:00pm-7:00pm

Safety, Efficacy, and Cost Saving Potential of Various Weight-Based Dosing for Thymoglobulin Induction Therapy in Kidney Transplant Recipients.

R. Miller,¹ H. Meadows,¹ S. Strout,¹ T. Veasey,¹ A. Mardis,¹ J. Fleming,¹ C. Mardis,¹ N. Pilch,¹ K. Chavin,² D. Taber.²

6:00pm-7:00pm

Serum Levels of Soluble Myeloid Antigens After Kidney Allograft Transplantation.

I. Striz, E. Cecrdlova, A. Sekerkova, J. Slatinska, V. Svachova, O. Viklicky.

6:00pm-7:00pm

Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients.

Q. Huang, X. Luo, M. McAdams-DeMarco, D. Segev.